Journal
TRENDS IN CANCER
Volume 2, Issue 12, Pages 758-770Publisher
CELL PRESS
DOI: 10.1016/j.trecan.2016.10.016
Keywords
-
Categories
Funding
- American Cancer Society
- Cindy Rosencrans Fund for TripleNegative Breast Cancer
- Department of Defense Breast Cancer Research Program
Ask authors/readers for more resources
Intratumoral hypoxia (reduced O-2 availability) is a common finding in human cancer and leads to increased activity of hypoxia-inducible factors (HIFs), which regulate the expression of genes that contribute to angiogenesis, metabolic reprogramming, extracellular matrix remodeling, epithelial-mesenchymal transition, motility, invasion, metastasis, cancer stem cell maintenance, immune evasion, and resistance to chemotherapy and radiation therapy. Conventional anticancer therapies target well-oxygenated and proliferating cancer cells, whereas there are no approved therapies that target hypoxic cancer cells, despite growing clinical and experimental evidence indicating that intratumoral hypoxia is a critical microenvironmental factor driving cancer progression. In this review, our current understanding of the consequences of HIF activity and the translational potential of targeting HIFs for cancer therapy are discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available